Captrust Financial Advisors Alaunos Therapeutics, Inc. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.89 $1,155 - $2,003	-1,060 Reduced 13.57%	6,750 $7,000
Q3 2021 Nov 16, 2021	BUY	$1.44 - $2.73 $1,526 - $2,893	1,060 Added 15.7%	7,810 $14,000
Q2 2021 Aug 16, 2021	SELL	$2.63 - $3.67 $2,119 - $2,958	-806 Reduced 10.67%	6,750 $18,000
Q1 2021 May 17, 2021	BUY	$2.82 - $5.6 $21,307 - $42,313	7,556 New	7,556 $27,000
Q4 2019 Feb 14, 2020	SELL	$3.95 - $5.35 $10,546 - $14,284	-2,670 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$4.13 - $6.94 $11,027 - $18,529	2,670 New	2,670 $11,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.